- Optiscan Imaging (OIL) completes the patient recruitment and imaging component of its breast cancer margin assessment trial
- The trial is to test Optiscan’s technology on 38 patients from Melbourne hospitals
- The main goal is to assess whether the technology can detect cancer cells while the surgery is ongoing, giving the opportunity for further cancerous tissue to be removed
- If successful, this will reduce the need for a second surgery, emotional trauma, physical pain and costs for the patients
- On the market today, Optiscan Imaging is up 2.27 per cent and is trading at 22.5 cents per share
Optiscan Imaging (OIL) has completed the patient recruitment and imaging component of its breast cancer margin assessment trial.
The trial is taking place at the Royal Melbourne Hospital, Frances Perry Hospital and Epworth Hospital.
So far, Optiscan has taken 42 breast cancer lumpectomy samples and associated cavity shaves from 38 patients, who recently underwent surgery.
The analysis of these images captured with Optiscan’s technology is underway, including comparisons with the current standard of care.
The main goal of this trial is to assess whether by using Optiscan’s technology cancerous cells can be detected while the surgery is ongoing, giving the opportunity for further cancerous tissue to be removed.
If successful, this will reduce the need for a second surgery, which is common for between 20 and 30 per cent of lumpectomy patients. The technology will also reduce emotional trauma, physical pain and costs for the patients, according to OIL.
The current standard of care means that the results of a second surgery could take a number of days.
On the market today, Optiscan Imaging was up 2.27 per cent and is trading at 22.5 cents per share at 11:33 am AEDT.